These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 31160357

  • 21. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
    Liu L, Hou F, Liu Y, Li W, Zhang H.
    J Natl Compr Canc Netw; 2021 Nov 11; 20(1):2-6. PubMed ID: 34763318
    [Abstract] [Full Text] [Related]

  • 22. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H, Nakajima T, Takeuchi K, Soda M, Mano H, Iizasa T, Matsui Y, Yoshino M, Shingyoji M, Itakura M, Itami M, Ikebe D, Yokoi S, Kageyama H, Ohira M, Nakagawara A.
    Lung Cancer; 2012 Jan 11; 75(1):66-72. PubMed ID: 21757253
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
    Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H, Cottrell CE, Pfeifer JD, Kulkarni S, Govindan R, Konnick EQ, Lockwood CM, Duncavage EJ.
    Mod Pathol; 2018 May 11; 31(5):791-808. PubMed ID: 29327716
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing P, Zhang Z, Chuai S, Li J, Ying J.
    Lung Cancer; 2018 Apr 11; 118():128-133. PubMed ID: 29571990
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
    Kang J, Chen HJ, Zhang XC, Su J, Zhou Q, Tu HY, Wang Z, Wang BC, Zhong WZ, Yang XN, Chen ZH, Ding Y, Wu X, Wang M, Fu JG, Yang Z, Zhang X, Shao YW, Wu YL, Yang JJ.
    Thorac Cancer; 2018 Sep 11; 9(9):1093-1103. PubMed ID: 29978950
    [Abstract] [Full Text] [Related]

  • 38. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC.
    J Thorac Oncol; 2017 Mar 11; 12(3):491-500. PubMed ID: 27836576
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. VIT-ALK, a Novel Alectinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    Hu S, Li Q, Peng W, Feng C, Zhang S, Li C.
    J Thorac Oncol; 2018 May 11; 13(5):e72-e74. PubMed ID: 29703539
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.